Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta.

Gilli F, De La Torre AL, Royce DB, Pachner AR.

Int Immunopharmacol. 2018 Sep;62:1-6. doi: 10.1016/j.intimp.2018.06.030. Epub 2018 Jun 27.

PMID:
29960044
2.

Pegylated interferon beta in the treatment of the Theiler's murine encephalomyelitis virus mouse model of multiple sclerosis.

Gilli F, Royce DB, DiSano KD, Pachner AR.

J Neuroimmunol. 2017 Dec 15;313:34-40. doi: 10.1016/j.jneuroim.2017.10.004. Epub 2017 Oct 9.

PMID:
29153606
3.

Treatment of Theiler's virus-induced demyelinating disease with teriflunomide.

Gilli F, Li L, Royce DB, DiSano KD, Pachner AR.

J Neurovirol. 2017 Dec;23(6):825-838. doi: 10.1007/s13365-017-0570-8. Epub 2017 Sep 14.

PMID:
28913765
4.

Maternal Antiviral Immunoglobulin Accumulates in Neural Tissue of Neonates To Prevent HSV Neurological Disease.

Jiang Y, Patel CD, Manivanh R, North B, Backes IM, Posner DA, Gilli F, Pachner AR, Nguyen LN, Leib DA.

MBio. 2017 Jul 5;8(4). pii: e00678-17. doi: 10.1128/mBio.00678-17.

5.

Sleep Loss Promotes Astrocytic Phagocytosis and Microglial Activation in Mouse Cerebral Cortex.

Bellesi M, de Vivo L, Chini M, Gilli F, Tononi G, Cirelli C.

J Neurosci. 2017 May 24;37(21):5263-5273. doi: 10.1523/JNEUROSCI.3981-16.2017.

6.

Multidimensional improvements induced by an intensive obesity inpatients rehabilitation programme.

Giordano F, Berteotti M, Budui S, Calgaro N, Franceschini L, Gilli F, Masiero M, Raschellà G, Salvetti S, Taddei M, Schena F, Busetto L.

Eat Weight Disord. 2017 Jun;22(2):329-338. doi: 10.1007/s40519-017-0393-x. Epub 2017 Apr 28.

PMID:
28455681
7.

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis.

Gilli F, Royce DB, Pachner AR.

J Vis Exp. 2016 Nov 14;(117). doi: 10.3791/54616.

PMID:
27911409
8.

High-Resolution Diffusion Tensor Spinal Cord MRI Measures as Biomarkers of Disability Progression in a Rodent Model of Progressive Multiple Sclerosis.

Gilli F, Chen X, Pachner AR, Gimi B.

PLoS One. 2016 Jul 28;11(7):e0160071. doi: 10.1371/journal.pone.0160071. eCollection 2016.

9.

The effect of B-cell depletion in the Theiler's model of multiple sclerosis.

Gilli F, Li L, Campbell SJ, Anthony DC, Pachner AR.

J Neurol Sci. 2015 Dec 15;359(1-2):40-7. doi: 10.1016/j.jns.2015.10.012. Epub 2015 Oct 8.

PMID:
26671084
10.

The immune response in the CNS in Theiler's virus induced demyelinating disease switches from an early adaptive response to a chronic innate-like response.

Gilli F, Li L, Pachner AR.

J Neurovirol. 2016 Feb;22(1):66-79. doi: 10.1007/s13365-015-0369-4. Epub 2015 Aug 11.

PMID:
26260496
11.

Chemokine biomarkers in central nervous system tissue and cerebrospinal fluid in the Theiler's virus model mirror those in multiple sclerosis.

Pachner AR, Li L, Gilli F.

Cytokine. 2015 Dec;76(2):577-580. doi: 10.1016/j.cyto.2015.06.010. Epub 2015 Jun 30.

PMID:
26141421
12.

Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-╬│ and interleukin-4 response.

Gilli F, Navone ND, Valentino P, Granieri L, Perga S, Malucchi S, Bertolotto A.

Mult Scler. 2012 Oct;18(10):1484-92. Epub 2012 May 4.

PMID:
22562951
13.

Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene.

Van Beers MM, Gilli F, Schellekens H, Randolph TW, Jiskoot W.

J Pharm Sci. 2012 Jan;101(1):187-99. doi: 10.1002/jps.22744. Epub 2011 Sep 14.

PMID:
21918983
14.

Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice.

van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W.

Pharm Res. 2011 Oct;28(10):2393-402. doi: 10.1007/s11095-011-0451-4. Epub 2011 May 5.

15.

Loss of braking signals during inflammation: a factor affecting the development and disease course of multiple sclerosis.

Gilli F, Navone ND, Perga S, Marnetto F, Caldano M, Capobianco M, Pulizzi A, Malucchi S, Bertolotto A.

Arch Neurol. 2011 Jul;68(7):879-88. doi: 10.1001/archneurol.2011.32. Epub 2011 Mar 14.

PMID:
21403007
16.

One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients.

Malucchi S, Gilli F, Caldano M, Sala A, Capobianco M, di Sapio A, Granieri L, Bertolotto A.

J Neurol. 2011 May;258(5):895-903. doi: 10.1007/s00415-010-5844-5. Epub 2010 Dec 12.

PMID:
21153733
17.

Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon beta.

Gilli F.

J Interferon Cytokine Res. 2010 Oct;30(10):733-41. doi: 10.1089/jir.2010.0098. Review.

PMID:
20874250
18.

Acute-phase proteins investigation based on lectins affinity capture prior to 2-DE separation: application to serum from multiple sclerosis patients.

Robotti A, Natale M, Albo AG, Lis K, Perga S, Marnetto F, Gilli F, Bertolotto A.

Electrophoresis. 2010 Sep;31(17):2882-93. doi: 10.1002/elps.201000171.

PMID:
20715125
19.

Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice.

van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W.

Pharm Res. 2010 Sep;27(9):1812-24. doi: 10.1007/s11095-010-0172-0. Epub 2010 May 25.

20.

Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.

van der Voort LF, Gilli F, Bertolotto A, Knol DL, Uitdehaag BM, Polman CH, Killestein J.

Arch Neurol. 2010 Apr;67(4):402-7. doi: 10.1001/archneurol.2010.21. Epub 2010 Feb 8.

PMID:
20142519
21.

Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis.

Gilli F, Lindberg RL, Valentino P, Marnetto F, Malucchi S, Sala A, Capobianco M, di Sapio A, Sperli F, Kappos L, Calogero RA, Bertolotto A.

PLoS One. 2010 Jan 29;5(1):e8962. doi: 10.1371/journal.pone.0008962.

22.

Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta.

van Beers MM, Sauerborn M, Gilli F, Hermeling S, Brinks V, Schellekens H, Jiskoot W.

J Immunol Methods. 2010 Jan 31;352(1-2):32-7. doi: 10.1016/j.jim.2009.10.005. Epub 2009 Oct 24.

PMID:
19857496
23.

Western blot analysis for the detection of serum antibodies recognizing linear Aquaporin-4 epitopes in patients with Neuromyelitis Optica.

Marnetto F, Hellias B, Granieri L, Frau J, Patanella AK, Nytrova P, Sala A, Capobianco M, Gilli F, Bertolotto A.

J Neuroimmunol. 2009 Dec 10;217(1-2):74-9. doi: 10.1016/j.jneuroim.2009.10.002. Epub 2009 Oct 21.

PMID:
19850359
24.

Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.

Gilli F, Valentino P, Caldano M, Granieri L, Capobianco M, Malucchi S, Sala A, Marnetto F, Bertolotto A.

Neurology. 2008 Dec 9;71(24):1940-7. doi: 10.1212/01.wnl.0000327340.50284.8d. Epub 2008 Oct 29.

PMID:
18971450
25.

Interferon-beta responders and non-responders. A biological approach.

Bertolotto A, Gilli F.

Neurol Sci. 2008 Sep;29 Suppl 2:S216-7. doi: 10.1007/s10072-008-0941-2. Review.

PMID:
18690496
26.

Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.

van der Voort LF, Kok A, Visser A, Oudejans CB, Caldano M, Gilli F, Bertolotto A, Polman CH, Killestein J.

Mult Scler. 2009 Feb;15(2):212-8. doi: 10.1177/1352458508096877. Epub 2008 Sep 19.

PMID:
18805837
27.

Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera.

Gilli F, van Beers M, Marnetto F, Jiskoot W, Bertolotto A, Schellekens H.

J Immunol Methods. 2008 Jul 31;336(2):119-26. doi: 10.1016/j.jim.2008.04.002. Epub 2008 Apr 28.

PMID:
18558408
28.

Predictive markers for response to interferon therapy in patients with multiple sclerosis.

Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A.

Neurology. 2008 Mar 25;70(13 Pt 2):1119-27. doi: 10.1212/01.wnl.0000304040.29080.7b. Epub 2008 Feb 13.

PMID:
18272865
29.

Anti-interferon-beta neutralising activity is not entirely mediated by antibodies.

Gilli F, Marnetto F, Caldano M, Valentino P, Granieri L, Di Sapio A, Capobianco M, Sala A, Malucchi S, Kappos L, Lindberg RL, Bertolotto A.

J Neuroimmunol. 2007 Dec;192(1-2):198-205. Epub 2007 Oct 22.

PMID:
17950468
30.

Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease).

Capobianco M, Malucchi S, di Sapio A, Gilli F, Sala A, Bottero R, Marnetto F, Doriguzzi Bozzo C, Bertolotto A.

Neurol Sci. 2007 Aug;28(4):209-11. Epub 2007 Aug 10.

PMID:
17690854
31.

Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.

Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, Marnetto F, Gilli F.

J Immunol Methods. 2007 Apr 10;321(1-2):19-31. Epub 2007 Feb 20.

PMID:
17335844
32.

Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis.

Gilli F, Hoffmann F, Sala A, Marnetto F, Caldano M, Valentino P, Kappos L, Bertolotto A, Lindberg RL.

Mult Scler. 2006 Dec;12(6):738-46.

PMID:
17263001
33.

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.

Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Capobianco M, Bertolotto A.

Mult Scler. 2006 Feb;12(1):47-57.

PMID:
16459719
34.

Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments.

Malucchi S, Capobianco M, Gilli F, Marnetto F, Caldano M, Sala A, Bertolotto A.

Neurol Sci. 2005 Dec;26 Suppl 4:S213-4.

PMID:
16388361
35.

Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis.

Gilli F, Marnetto F, Stefanuto G, Rinaldi V, Farinazzo F, Malucchi S, Capobianco M, Caldano M, Sala A, Bertolotto A.

Mol Diagn. 2004;8(3):185-94.

PMID:
15771557
36.

Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.

Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Di Sapio A, Capobianco M, Bertolotto A.

J Neuroimmunol. 2005 Jan;158(1-2):195-203.

PMID:
15589054
37.

Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.

Bertolotto A, Sala A, Malucchi S, Marnetto F, Caldano M, Di Sapio A, Capobianco M, Gilli F.

J Neurol Neurosurg Psychiatry. 2004 Sep;75(9):1294-9.

38.

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis.

Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, Bertolotto A.

Neurology. 2004 Jun 8;62(11):2031-7.

PMID:
15184610
39.

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

Gilli F, Bertolotto A, Sala A, Hoffmann F, Capobianco M, Malucchi S, Glass T, Kappos L, Lindberg RL, Leppert D.

Brain. 2004 Feb;127(Pt 2):259-68. Epub 2003 Nov 7.

PMID:
14607790
40.

Neuromyelitis optica: importance of cerebrospinal fluid examination during relapse.

Milano E, Di Sapio A, Malucchi S, Capobianco M, Bottero R, Sala A, Gilli F, Bertolotto A.

Neurol Sci. 2003 Oct;24(3):130-3.

PMID:
14600824
41.

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E, Melis F, Marnetto F, Lindberg RL, Bottero R, Di Sapio A, Giordana MT.

Neurology. 2003 Feb 25;60(4):634-9.

PMID:
12601105
42.

Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients.

Gilli F, Sala A, Bancone C, Salacone P, Gallo M, Gaia E, Bertolotto A.

J Immunol Methods. 2002 Apr 1;262(1-2):187-90.

PMID:
11983232
43.

Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification.

Bertolotto A, Gilli F, Sala A, Audano L, Castello A, Magliola U, Melis F, Giordana MT.

J Immunol Methods. 2001 Oct 1;256(1-2):141-52.

PMID:
11516761

Supplemental Content

Support Center